Epstein H, Hardy R, May J S, Johnson M H, Holmes N
Department of Pathology, Cambridge University.
Eur J Immunol. 1989 Sep;19(9):1575-83. doi: 10.1002/eji.1830190909.
We have derived a number of transgenic mouse lines which express the human major histocompatibility complex class I gene HLA-A2.1. Two lines carry the complete human HLA-A2.1, the others bear a recombinant gene in which the HLA-A2.1 coding regions are fused to the H-2Kb promoter. Analysis of transgenic spleen cells by immunofluorescence demonstrates that these mouse cells express HLA-A2.1 on their surface in association with mouse beta 2-microglobulin (beta 2m), confirming that HLA-A2 does not require human beta 2m to be expressed at the cell surface. The cells contain more HLA mRNA than endogenous H-2 class I mRNA. There is also a large pool of non-beta 2m-associated HLA heavy chain inside the cell. In contrast the amount of HLA:beta 2m complex is low. Thus, in transgenic mice HLA-A2 seems to compete poorly with H-2 heavy chains for mouse beta 2m. The HLA-A2.1 transgenic mice do not produce influenza-virus-specific cytotoxic T cells (CTL) restricted to the HLA transgene, at least in sufficient numbers to be measured in a direct bulk CTL assay. The dominance of H-2-restricted clones may be the result of quantitative rather than qualitative factors. However, HLA-A2.1 transgenic spleen cells are effective in stimulating an allogeneic CTL response in normal mice. This response is not H-2 restricted. Cold target inhibition studies show that there are at least two populations of CTL, one of which is specific for HLA-A2.1 on mouse cells. This result suggests that at least some allo-CTL are directed against major histocompatibility complex plus "self-peptide".
我们已经培育出了一些表达人类主要组织相容性复合体I类基因HLA - A2.1的转基因小鼠品系。其中两个品系携带完整的人类HLA - A2.1,其他品系带有一个重组基因,该重组基因中HLA - A2.1的编码区与H - 2Kb启动子融合。通过免疫荧光分析转基因脾细胞表明,这些小鼠细胞在其表面表达与小鼠β2 - 微球蛋白(β2m)相关联的HLA - A2.1,证实HLA - A2在细胞表面表达不需要人类β2m。这些细胞中HLA mRNA的含量比内源性H - 2 I类mRNA多。细胞内还有大量与β2m不相关的HLA重链。相比之下,HLA:β2m复合体的量较低。因此,在转基因小鼠中,HLA - A2似乎与H - 2重链竞争小鼠β2m的能力较差。HLA - A2.1转基因小鼠至少在直接的大量细胞毒性T细胞(CTL)检测中不能产生足够数量的受HLA转基因限制的流感病毒特异性CTL。H - 2限制克隆的优势可能是数量而非质量因素的结果。然而,HLA - A2.1转基因脾细胞在刺激正常小鼠的同种异体CTL反应方面是有效的。这种反应不受H - 2限制。冷靶抑制研究表明至少有两个CTL群体,其中一个对小鼠细胞上的HLA - A2.1具有特异性。这一结果表明至少一些同种异体CTL是针对主要组织相容性复合体加“自身肽”的。